PN 79106
RN 01086 
AN 79151454
AU Seale-T-W.  Thirkill-H.  Tarpay-M.  Flux-M.  Rennert-O-M.
TI Serotypes and antibiotic susceptibilities of Pseudomonas aeruginosa
   isolates from single sputa of cystic fibrosis patients.
SO J-Clin-Microbiol. 1979 Jan. 9(1). P 72-8.
MJ CYSTIC-FIBROSIS: mi.  PSEUDOMONAS-AERUGINOSA: cl.  SPUTUM: mi.
MN ADOLESCENCE.  ADULT.  ANTIBIOTICS: pd.  CHILD.  CHILD-PRESCHOOL.
   DRUG-RESISTANCE-MICROBIAL.  HAEMOPHILUS-INFLUENZAE: ip.  HUMAN.
   PSEUDOMONAS-AERUGINOSA: de.  SEROTYPING.  STAPHYLOCOCCUS-AUREUS: ip.
   SUPPORT-U-S-GOVT-P-H-S.
AB A phenotypic characterization of Pseudomonas aeruginosa from single
   sputum samples of 21 typical cystic fibrosis patients indicated a
   high frequency of heterogeneity among isolates on the basis of
   differences in antibiotic resistance, colony morphology,
   pigmentation, and serotype.  Two or more isolates with different but
   stable susceptibilities to carnecillin, gentamycin, streptomycin,
   tetracycline, chloramphenicol, and sulfamethoxazole plus
   trimethoprim were detected in 38% of the sputa.  Differences
   generally were independent of the mucoid state of the strain.  O-
   antigen group determination with the Difco typing set showed that
   two or more serologically distinct strains were present in 10/21
   sputum specimens.  Nonmucoid derivatives of mucoid isolates almost
   always retained both the antibiotic susceptibilities and serotype of
   their parent strain.  These data suggest that cystic fibrosis
   patients may be cocolonized/coinfected by difference strains of P.
   aeruginosa more frequently than generally believed.  Alternatively,
   phenotypically distinct strains from a single patient might arise as
   phenotypic dissociants from a single infecting strain.  Because of
   the frequency and multiplicity of phenotypically distinct P.
   aeruginosa isolates which we obtained from our cystic fibrosis
   patients, it is important to select multiple isolates from sputum
   cultures for antimicrobial susceptibility testing so as to assess
   adequately the susceptibility of this organism to antibiotic therapy
   in cystic fibrosis.  We recommend that several colonies of each
   distinguishable colony type of P. aeruginosa be pooled for the
   antibiogram.
RF 001   BAUER AW              AM J CLIN PATHOL                45   493 966
   002   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   003   BOWMAN BH             IN: MANGOS JA                        277 976
   004   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   005   DIAZ F                J INFECT DIS                   121   269 970
   006   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   007   DOGGETT RG            J PEDIATR                       68   215 966
   008   GRIEBLE HG            N ENGL J MED                   282   531 970
   009   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     1 977
   010   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   011   LEVISON H             IN: MANGOS JA                          3 976
   012   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   013   SCHWARZMANN S         INFECT IMMUN                     3   762 971
   014   TALAMO RC             IN: MANGOS JA                        195 976
   015   WILLIAMS RJ           J MED MICROBIOL                  6   409 973
   016   ZIERDT CH             J BACTERIOL                     87  1003 964
   017   ZIERDT CH             J CLIN MICROBIOL                 1   521 975
CT   1   DEMKO CA              CURRENT MICROBIOL                4    69 980
     2   MARKOWITZ SM          J ANTIMICROB CHEMOTHER           6   251 980
     3   GODFREY AJ            ANTIMICROB AGENTS CHEMOTHER     19   705 981
     4   IRVIN RT              ANTIMICROB AGENTS CHEMOTHER     19  1056 981
     5   WILSON LA             AM J OPHTHALMOL                 92   546 981
     6   MARKS MI              J PEDIATR                       98   173 981
     7   SEALE TW              ANN CLIN LAB SCI                12   415 982
     8   JANDA JM              J CLIN MICROBIOL                15   178 982
     9   SHEEHAN DJ            J CLIN MICROBIOL                15   926 982
    10   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    11   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    12   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    13   ANON                  LANCET                           2   257 983
    14   GOVAN JRW             REV INFECT DIS                   5  S874 983
    15   JAGGER KN             J CLIN MICROBIOL                17    55 983
    16   FLOURNOY DJ           METH FIND EXP CLIN PHARMACOL     6   487 984
    17   CHAN R                J CLIN MICROBIOL                19     8 984
    18   MCNEILL WF            AM J CLIN PATHOL                81   742 984
    19   GOLD R                PEDIATR INFECT DIS               4   172 985
    20   LUZAR MA              INFECT IMMUN                    50   577 985
    21   KOMIYAMA K            ORAL SURG                       59   590 985
    22   BERKIN KE             EUR J RESPIR DIS                67   103 985
    23   PIER GB               J INFECT DIS                   151   575 985
    24   PACIFICO L            J INFECT DIS                   152   852 985
    25   MAYO MS               J CLIN MICROBIOL                24   372 986
    26   PIER GB               J CLIN MICROBIOL                24   189 986
    27   KOMIYAMA K            CAN J MICROBIOL                 33   221 987
    28   OGLE JW               J INFECT DIS                   155   119 987